Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

J. Naidoo, D. B. Page, B. T. Li, L. C. Connell, K. Schindler, M. E. Lacouture, M. A. Postow, J. D. Wolchok

Research output: Contribution to journalArticlepeer-review

682 Scopus citations


Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained recent regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and nonsmall-cell lung cancer. Knowledge of toxicities associated with PD-1/PD-L1 blockade, as well as effective management algorithms for these toxicities, is pivotal in order to optimize clinical efficacy and safety. In this article, we review selected published and presented clinical studies investigating singleagent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anticancer therapies, in multiple tumor types. We summarize the key adverse events reported in these studies and their management algorithms.

Original languageEnglish (US)
Pages (from-to)2375-2391
Number of pages17
JournalAnnals of Oncology
Issue number12
StatePublished - Dec 1 2015


  • Adverse event
  • Anti-PD-1
  • Anti-PD-L1
  • Immune checkpoint antibody
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies'. Together they form a unique fingerprint.

Cite this